Clinical trials: Hematological Patients
Hematological Malignancies, Invasive Fungal Disease
mNGS for IFD in Patients With Hematological Malignancies
Invasive fungal disease (IFD) refers to an infectious disease caused by fungi invading the human body, growing and reproducing in tissues, organs, or blood, and leading to inflammatory responses and tissue damage.
- Trial name
- NCT07763184
- Testing
- metagenomic next-generation sequencing
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematological Diseases, Allogeneic Stem Cell Transplantation
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
The primary objective of this study is to evaluate the efficacy and safety profile of itraconazole as in primary prophylaxis The second objective of this study is to find the difference between long-term versus short-term…
- Trial name
- NCT01160952
- Testing
- itraconazole
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations.
- Conditions
- Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1
- Trial name
- NCT05735184
- Testing
- Ziftomenib, Venetoclax, Azacitidine
- Where
- 44 sites in United States
- Volunteers
- 420 people
- Sponsor
- Kura Oncology, Inc.
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
This phase I/II clinical investigation is designed to determine the safety and anti-tumor effects of intravenous administration of the experimental immunotherapy drug, called AlloStim.
- Trial name
- NCT00861965
- Testing
- AlloStim-8
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mirror Biologics, Inc.
Hematologic Diseases
The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study
Each year, 17000 cases of severe hematological diseases are diagnosed in France, with more than 6,000 of these requiring hospitalization in a protective, sterile environment.
- Trial name
- TANDHEMS (NCT02343965)
- Testing
- Touch-massage
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Nantes University Hospital
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cancer, Sleep Disturbance
Wellness App for Sleep Disturbance in Hematological Cancer Patients
In a randomized controlled trial (RCT), the investigators will recruit participants to an 8-week "app-based wellness" intervention, followed by a 12-week follow-up period.
- Conditions
- Cancer, Sleep Disturbance, Anxiety, Depression
- Trial name
- Heme (NCT05294991)
- Testing
- Wellness app intervention #1, Wellness app intervention #2
- Where
- 3 sites in United States
- Volunteers
- 276 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Acute Graft-versus-host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation…
- Trial name
- NCT06294678
- Testing
- Time of stem cell infusion
- Where
- 6 sites in China
- Volunteers
- 198 people
- Sponsor
- Anhui Provincial Hospital
Respiratory Insufficiency, Hematologic Malignancy
Systematic Evaluation by an Intensivist of Hematological Malignancy Patients Presenting With Acute Respiratory or Hemodynamic Failure
Over the last two decades, the number of patients with hematological malignancies (HMs) admitted to the ICU increased and their mortality has dropped sharply.
- Trial name
- CAREHEMA (NCT03399149)
- Testing
- Systematic evaluation by an intensivist
- Where
- 2 sites in France
- Volunteers
- 221 people
- Sponsor
- University Hospital, Grenoble
Hematological Malignancies
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present.
- Trial name
- NCT00438178
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 3 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Gemin X
Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease
Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors
This is a multi-center, prospective, open, observational and optimal clinical research to evaluate the clinical effectiveness and safety of different doses of micafungin sodium for injection in patients with hematological tumors.
- Trial name
- NCT04738955
- Testing
- Micafungin Sodium
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Shandong Provincial Hospital
Hematopoietic and Lymphoid Cell Neoplasm
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
This phase I trial studies the side effects and best dose of donor cord blood T-cells after stem cell transplant in treating patients with relapsed hematological malignancies.
- Trial name
- NCT01630564
- Testing
- Aldesleukin, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion, Umbilical Cord Blood-Derived Lymphocyte Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Nausea and Vomiting Chemotherapy-Induced, Hematological Malignancies
The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting
The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting in Patients With Hematological Malignancies ABSTRACT Background: Chemotherapy is widely used in the treatment of hematological malignancies…
- Trial name
- NCT07456982
- Testing
- Relaxation breathing exercise, Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people
- Sponsor
- Marmara University
Blood Cancer, Multiple Myeloma (MM)
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress.
- Conditions
- Blood Cancer, Multiple Myeloma (MM), Lymphoma
- Trial name
- NCT06817759
- Testing
- Virtual Reality Hypnosis, VRH : Beach, VRH : Forest
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Sarcomas, Haematological Malignancies
Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors
The study aims to test for the presence or absence of primary tumor-specific tumor markers in ovarian tissue. Therefore, there will be a first phase in which pathology-specific markers will be identified in the patients'…
- Trial name
- NCT06829654
- Testing
- Step 1, Step 2, Step 3
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04488354
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Calibr, a division of Scripps Research
Myelodysplastic Syndromes
Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes
A phase I study of azacitidine with Ceplene/interleukin-2 will first evaluate the safety and tolerability of this regimen in patients with higher risk myelodysplastic syndromes (MDS) who achieved a hematological response after 6…
- Trial name
- NCT01324960
- Testing
- Ceplene®, IL-2, Azacitidine, Azacitidine
- Where
- 28 sites in France
- Sponsor
- Groupe Francophone des Myelodysplasies
Advanced Solid Tumors, Hematologic Malignancies
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing…
- Trial name
- SPI-FOL-102 (NCT07036133)
- Testing
- Pralatrexate Injection
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acrotech Biopharma Inc.
Lymphoma Neoplasms, Myeloma Multiple
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy.
- Conditions
- Lymphoma Neoplasms, Myeloma Multiple, Severe Infection, CMV Reactivation
- Trial name
- NCT07609576
- Where
- 2 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Infanta Leonor University Hospital
Invasive Aspergillosis
Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis
The investigators hypothesize that early galactomannan and beta-D-glucan features, namely the height of the initial value at the time of diagnosis and the subsequent rate of marker decay within the first week(s) following therapy…
- Trial name
- NCT01176071
- Volunteers
- 50 people
- Sponsor
- University Hospital, Gasthuisberg